Takeda Pharmaceutical Co (FRA:TKD) E10: €0.78 (As of Mar. 2026)


FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
68 GF Score
Price €27.73
GF Value €24.70
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co E10?

Takeda Pharmaceutical Co FRA:TKD +1.72% 68 E10 is €0.78 as of Mar. 2026. GuruFocus rates FRA:TKD with a GF Score™ of 68/100 and a GF Value™ of €24.70 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Takeda Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was €-1.276. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.78 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Takeda Pharmaceutical Co's average E10 Growth Rate was -11.90% per year. During the past 3 years, the average E10 Growth Rate was 2.80% per year. During the past 5 years, the average E10 Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Takeda Pharmaceutical Co was 8.30% per year. The lowest was -11.80% per year. And the median was -1.60% per year.

As of today (2026-06-29), Takeda Pharmaceutical Co's current stock price is €27.73. Takeda Pharmaceutical Co's E10 for the quarter that ended in Mar. 2026 was €0.78. Takeda Pharmaceutical Co's Shiller PE Ratio of today is 35.55.

During the past 13 years, the highest Shiller PE Ratio of Takeda Pharmaceutical Co was 41.12. The lowest was 19.53. And the median was 29.69.


Takeda Pharmaceutical Co  (FRA:TKD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Takeda Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=27.73/0.78
=35.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Takeda Pharmaceutical Co was 41.12. The lowest was 19.53. And the median was 29.69.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Takeda Pharmaceutical Co E10 Related Terms


Takeda Pharmaceutical Co E10 Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co E10 Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.90 0.78 0.98 0.78

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.97 0.91 0.86 0.78

FRA:TKD vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Shiller PE Ratio falls into.


FRA:TKD
68GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Takeda Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.276/112.7000*112.7000
=-1.276

Current CPI (Mar. 2026) = 112.7000.

Takeda Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201606 1.071 98.100 1.230
201609 0.277 98.000 0.319
201612 0.431 98.400 0.494
201703 -0.538 98.100 -0.618
201706 1.480 98.500 1.693
201709 0.270 98.800 0.308
201712 0.648 99.400 0.735
201803 -0.530 99.200 -0.602
201806 0.774 99.200 0.879
201809 0.470 99.900 0.530
201812 0.375 99.700 0.424
201903 -0.150 99.700 -0.170
201906 0.037 99.800 0.042
201909 0.366 100.100 0.412
201912 -0.171 100.500 -0.192
202003 0.009 100.300 0.010
202006 0.435 99.900 0.491
202009 0.021 99.900 0.024
202012 0.464 99.300 0.527
202103 0.968 99.900 1.092
202106 0.659 99.500 0.746
202109 0.224 100.100 0.252
202112 0.285 100.100 0.321
202203 -0.055 101.100 -0.061
202206 0.477 101.800 0.528
202209 0.278 103.100 0.304
202212 0.531 104.100 0.575
202303 0.135 104.400 0.146
202306 0.373 105.200 0.400
202309 -0.194 106.200 -0.206
202312 0.426 106.800 0.450
202403 -0.012 107.200 -0.013
202406 0.353 108.200 0.368
202409 0.360 108.900 0.373
202412 0.091 110.700 0.093
202503 -0.406 111.100 -0.412
202506 0.469 111.700 0.473
202509 -0.045 112.000 -0.045
202512 0.354 113.000 0.353
202603 -1.276 112.700 -1.276

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.78 mean?
Takeda Pharmaceutical Co (FRA:TKD) has a E10 of €0.78 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's E10 too high?
Takeda Pharmaceutical Co's current E10 is €0.78. Overall, Takeda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's E10 compare to ZTS and UTHR?
Takeda Pharmaceutical Co's E10 of €0.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current E10 is €0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (FRA:TKD) is currently considered Modestly Overvalued. The stock's GF Value™ is €24.70, compared to a current price of €27.73 — trading 12.3% above its estimated fair value. The current E10 is €0.78. Takeda Pharmaceutical Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Takeda Pharmaceutical Co (FRA:TKD), the current E10 is €0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €27.73 is trading 12.3% above its estimated GF Value™ of €24.70. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • E10: €0.78
  • GF Value™: €24.70 vs. price of €27.73 (12.3% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
68GF Score

Get the complete analysis for FRA:TKD

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.73
Price
€24.70
GF Value